<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01208662</url>
  </required_header>
  <id_info>
    <org_study_id>10-106</org_study_id>
    <nct_id>NCT01208662</nct_id>
  </id_info>
  <brief_title>Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65</brief_title>
  <acronym>DFCI 10-106</acronym>
  <official_title>A Randomized, Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib, and Dexamethasone (RVD) to High-Dose Treatment With Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients Up to 65 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Paul G. Richardson, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cape Cod Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fox Chase Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UNC Lineberger Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Mississippi Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>OHSU Knight Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eastern Maine Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pittsburgh Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ochsner Health System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>State University of New York - Downstate Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Newton-Wellesley Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Northwell Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huntsman Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The drugs, lenalidomide, bortezomib, and dexamethasone, are approved by the FDA. They have&#xD;
      not been approved in the combination for multiple myeloma or any other type of cancer.&#xD;
      Bortezomib is currently approved by the FDA for the treatment of multiple myeloma.&#xD;
      Lenalidomide is approved for use with dexamethasone for patients with multiple myeloma who&#xD;
      have received at least one prior therapy and for the treatment of certain types of&#xD;
      myelodysplastic syndrome (another type of cancer affecting the blood). Dexamethasone is&#xD;
      commonly used, either alone, or in combination with other drugs, to treat multiple myeloma.&#xD;
      Please note that Bortezomib and Lenalidomide are provided to patients participating in this&#xD;
      trial at no charge. Melphalan and cyclophosphamide, the drugs used during stem cell&#xD;
      collection and transplant, are also approved by the FDA. Melphalan is an FDA-approved&#xD;
      chemotherapy for multiple myeloma and is used as a high-dose conditioning treatment prior to&#xD;
      stem cell transplantation. Cyclophosphamide is used, either alone, or in combination with&#xD;
      other drugs, to treat multiple myeloma. These drugs have been used in other multiple myeloma&#xD;
      studies and information from those studies suggests that this combination of therapy may help&#xD;
      to treat newly diagnosed multiple myeloma.&#xD;
&#xD;
      In this research study, we are looking to explore the drug combination, lenalidomide,&#xD;
      bortezomib and dexamethasone alone or when combined with autologous stem cell transplantation&#xD;
      to see what side effects it may have and how well it works for treatment of newly diagnosed&#xD;
      multiple myeloma. Specifically, the objective of this trial is to determine if, in the era of&#xD;
      novel drugs, high dose therapy (HDT) is still necessary in the initial management of multiple&#xD;
      myeloma in younger patients. In this study, HDT as compared to conventional dose treatment&#xD;
      would be considered superior if it significantly prolongs progression-free survival by at&#xD;
      least 9 months or more, recognizing that particular subgroups may benefit more compared to&#xD;
      others.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After screening procedures determine if a patient is eligible for this research study, the&#xD;
      patient will be randomized into one of the study groups: lenalidomide, bortezomib and&#xD;
      dexamethasone without autologous stem cell transplantation, followed by lenalidomide&#xD;
      maintenance (Arm A) or lenalidomide, bortezomib and dexamethasone with autologous stem cell&#xD;
      transplantation, followed by lenalidomide maintenance (Arm B). There is an equal chance of&#xD;
      being placed in either group.&#xD;
&#xD;
      All participants will receive one cycle of lenalidomide, bortezomib and dexamethasone&#xD;
      treatment before being randomized to Arm A or Arm B.&#xD;
&#xD;
      Participants in Arm A will receive two additional cycles of lenalidomide, bortezomib and&#xD;
      dexamethasone prior to stem cell collection. If randomized to Arm A, the subject will undergo&#xD;
      stem cell collection, followed by five cycles of lenalidomide, bortezomib and dexamethasone.&#xD;
      This will be followed by lenalidomide maintenance treatment until disease progression.&#xD;
&#xD;
      Participants in Arm B will receive two additional cycles of lenalidomide, bortezomib and&#xD;
      dexamethasone prior to stem cell collection. If randomized to Arm B, the subject will undergo&#xD;
      stem cell collection and autologous stem cell transplantation, followed by two cycles of&#xD;
      lenalidomide, bortezomib and dexamethasone. This will be followed by lenalidomide maintenance&#xD;
      treatment until disease progression.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Outcome</measure>
    <time_frame>Up to 6 years or until progression</time_frame>
    <description>To compare progression-free survival (PFS) between Arm A and Arm B.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome</measure>
    <time_frame>Up to 6 years or until progression</time_frame>
    <description>To compare the response rates (RR) between the two arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome</measure>
    <time_frame>Up to 6 years or until progression</time_frame>
    <description>To compare time to progression (TTP) between the two arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome</measure>
    <time_frame>Up to 6 years or until progression</time_frame>
    <description>To compare the overall survival (OS) between the two arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome</measure>
    <time_frame>Up to 6 years or until progression</time_frame>
    <description>To compare toxicity between the two arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome</measure>
    <time_frame>Up to 6 years or until progression</time_frame>
    <description>To define genetic prognostic groups evaluated by gene expression profiling (GEP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcomes</measure>
    <time_frame>Up to 6 years or until progression</time_frame>
    <description>To examine the best treatment in each GEP-defined prognostic group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome</measure>
    <time_frame>Up to 6 years or until progression</time_frame>
    <description>To compare quality of life (QOL) between the two arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome</measure>
    <time_frame>Up to 6 years or until progression</time_frame>
    <description>To collect medical resource utilization (MRU) information which may be used in economic evaluation models.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">660</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>High Dose Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lenalidomide, bortezomib, dexamethasone. Stem cell collection. Maintenance Lenalidomide.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose Treatment with SCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lenalidomide, bortezomib, dexamethasone. Stem cell collection. Autologous Stem Cell Transplant. Maintenance Lenalidomide.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Oral, 25 mg/day, days 1-14 for 8 total cycles for Arm A. Oral, 25 mg/day, days 1-14 for 5 total cycles for Arm B.&#xD;
Oral, 10-15 mg/day, daily for 12 months in maintenance for Arm A and Arm B.</description>
    <arm_group_label>High Dose Treatment</arm_group_label>
    <arm_group_label>High Dose Treatment with SCT</arm_group_label>
    <other_name>CC-5013</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>IV, days 1, 4, 8 and 11 for 8 total cycles for Arm A. IV, days 1, 4, 8 and 11 for 5 total cycles for Arm B.</description>
    <arm_group_label>High Dose Treatment</arm_group_label>
    <arm_group_label>High Dose Treatment with SCT</arm_group_label>
    <other_name>PS-341</other_name>
    <other_name>Velcade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Oral, days 1, 2, 4, 5, 8, 9, 11 and 12 for 8 total cycles for Arm A. Oral, days 1, 2, 4, 5, 8, 9, 11 and 12 for 5 total cycles for Arm B.&#xD;
Dose of 20 mg/day for first 3 cycles. Dose of 10 mg/day for remaining cycles.</description>
    <arm_group_label>High Dose Treatment</arm_group_label>
    <arm_group_label>High Dose Treatment with SCT</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous Stem Cell Transplant</intervention_name>
    <description>Stem cell transplant</description>
    <arm_group_label>High Dose Treatment with SCT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Multiple Myeloma, according to the International Myeloma Foundation 2003&#xD;
             Diagnostic Criteria&#xD;
&#xD;
          -  Documented symptomatic myeloma, with organ damage related to myeloma with laboratory&#xD;
             assessments performed within 21 days of registration&#xD;
&#xD;
          -  Myeloma that is measurable by either serum or urine evaluation of the monoclonal&#xD;
             component or by assay of serum free light chains.&#xD;
&#xD;
          -  ECOG performance status &lt;/= 2&#xD;
&#xD;
          -  Negative HIV blood test&#xD;
&#xD;
          -  Voluntary written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating female&#xD;
&#xD;
          -  Prior systemic therapy for MM (localized radiotherapy allowed if at least 7 days&#xD;
             before study entry, corticosteroids allowed if dose &lt;/= equivalent of 160 mg&#xD;
             dexamethasone over 2 weeks)&#xD;
&#xD;
          -  Primary amyloidosis (AL) or myeloma complicated by amylosis&#xD;
&#xD;
          -  Receiving any other investigational agents&#xD;
&#xD;
          -  Known brain metastases&#xD;
&#xD;
          -  Poor tolerability or allergy to any of the study drugs or compounds of similar&#xD;
             composition&#xD;
&#xD;
          -  Platelet count &lt;50,000/mm3, within 21 days of registration&#xD;
&#xD;
          -  ANC &lt;1,000 cells/mm3, within 21 days of registration&#xD;
&#xD;
          -  Hemoglobin &lt;8 g/dL, within 21 days of registration&#xD;
&#xD;
          -  Hepatic impairment (&gt;/= 1.5 x institutional ULN or AST (SGOT), ALT (SGPT), or alkaline&#xD;
             phosphatase &gt;2 x ULN). Patients with benign hyperbilirubinemia are eligible.&#xD;
&#xD;
          -  Renal insufficiency (serum creatinine &gt;2.0 mg/dl or creatinine clearance &lt;50 ml/min,&#xD;
             within 21 days of registration)&#xD;
&#xD;
          -  Respiratory compromise (DLCO &lt; 50%)&#xD;
&#xD;
          -  Clinical signs of heart or coronary failure or LVEF &lt; 40%. Myocardial infarction&#xD;
             within 6 months prior to enrollment, NYHA Class III or IV heart failure, uncontrolled&#xD;
             angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence&#xD;
             of acute ischemia or active conductive system abnormalities&#xD;
&#xD;
          -  Intercurrent illness including, but not limited to ongoing or active severe infection,&#xD;
             known infection with hepatitis B or C virus, poorly controlled diabetes, severe&#xD;
             uncontrolled psychiatric disorder or psychiatric illness/social situations that would&#xD;
             limit compliance with study requirements&#xD;
&#xD;
          -  Previous history of another malignant condition except for basal cell carcinoma and&#xD;
             stage I cervical cancer. If malignancy was experienced more than 2 years ago and&#xD;
             confirmed as cured, these participants may be considered for the study on case by case&#xD;
             basis with PI discussion.&#xD;
&#xD;
          -  Inability to comply with an anti-thrombotic treatment regimen&#xD;
&#xD;
          -  Peripheral neuropathy &gt;/= Grade 2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul G. Richardson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Comprehensive Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California at San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Blood Cancer Institute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mountain States Tumor Institute at St. Luke's Regional Medical Center</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Foundation Clinic</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Maine Medical Center</name>
      <address>
        <city>Brewer</city>
        <state>Maine</state>
        <zip>04412</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cape Cod Healthcare</name>
      <address>
        <city>Hyannis</city>
        <state>Massachusetts</state>
        <zip>02601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newton-Wellesley Hospital</name>
      <address>
        <city>Newton</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Hampshire Oncology and Hematology</name>
      <address>
        <city>Concord</city>
        <state>New Hampshire</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Hampshire Oncology and Hematology</name>
      <address>
        <city>Hooksett</city>
        <state>New Hampshire</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Hampshire Oncology and Hematology</name>
      <address>
        <city>Laconia</city>
        <state>New Hampshire</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State University of New York Downstate Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore Long Island Jewish Health System</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNC Lineberger Comprehensive Cancer Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Sciences</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
  </removed_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 23, 2010</study_first_submitted>
  <study_first_submitted_qc>September 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2010</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Paul G. Richardson, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Lenalidomide</keyword>
  <keyword>Bortezomib</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Stem Cell Transplant</keyword>
  <keyword>Myeloma</keyword>
  <keyword>Multiple Myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

